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Aim: To develop the decerebrate arterially perfused mouse (DAPM) preparation, a
novel voiding model of the lower urinary tract (LUT) that enables in vitro-like access
with in vivo-like neural connectivity.
Methods: Adult male mice were decerebrated and arterially perfused with a
carbogenated, Ringer's solution to establish the DAPM. To allow distinction
between central and peripheral actions of interventions, experiments were
conducted in both the DAPM and in a “pithed” DAPM which has no brainstem
or spinal cord control.
Results: Functional micturition cycles were observed in response to bladder filling.
During each void, the bladder showed strong contractions and the external urethral
sphincter (EUS) showed bursting activity. Both the frequency and amplitude of non-
voiding contractions (NVCs) in DAPM and putativemicromotions (pMM) in pithed
DAPM increasedwith bladder filling.Vasopressin (>400 pM) caused dyssynergy of
the LUT resulting in retention in DAPM as it increased tonic EUS activity and basal
bladder pressure in a dose-dependent manner (basal pressure increase also noted in
pithed DAPM). Both neuromuscular blockade (vecuronium) and autonomic
ganglion blockade (hexamethonium), initially caused incomplete voiding, and
both drugs eventually stopped voiding in DAPM. Intravesical acetic acid (0.2%)
decreased the micturition interval. Recordings from the pelvic nerve in the pithed
DAPM showed bladder distention-induced activity in the non-noxious range which
was associated with pMM.
Conclusions: This study demonstrates the utility of the DAPM which allows a
detailed characterization of LUT function in mice.
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1 | INTRODUCTION
The micturition cycle consists of two-phases of bladder activity:
filling and voiding. This is achieved by the co-ordinated action of
both the autonomic and somatic motor system. A spinal-
brainstem-spinal loop is the core circuit controlling micturition
including the periaqueductal gray and pontine micturition center
(Barrington's nucleus). This circuit responds to afferent inputs
from the bladder to generate voiding.1,2 However, the neural
mechanisms thatgenerateandregulate thephasesofmicturition1,2
have not been fully elucidated in man nor in animal models.
Rodents are now the most common model species for neuro-
urological investigationsandhavebeenwidelyadopted for studies
of the lower urinary tract (LUT). Previously, we have reported a
decerebrate, arterially perfused rat (DAPR) preparation which
exhibited strong and consistent filling and voiding responses.3,4
This preparation permits the simultaneous measurement of
bladder pressure, external urethral sphincter-electromyogram
(EUS-EMG) and nerve recordings from pelvic or pudendal
nerves, as well as recordings of the phrenic nerve, electrocardio-
gram, and arterial pressure.4 However, a drawback of DAPR for
some types of studieswas the need to use young rats primarily due
to the challenge of establishing adequate tissue perfusion in larger
animals, which limited preparation viability.
Themouse is increasinglyused inneuroscience investigations
because of its genetic tractability and the ability to study the
influence of precise molecular interventions at a circuit level,
however, the study ofLUTcontrolmechanisms in themouse is in
its infancy.5 Therefore, to take advantage of this toolbox and
tractability and to overcome the size/age limitations of DAPRwe
have developed a decerebrate arterially perfusedmouse (DAPM)
preparation that allows the complete micturition cycle of adult
animals to be investigated.We show this approach can be used to
fill some of the current gaps in our knowledge regarding the
dynamics of murine neuro-urology5 by improving access to both
the LUT and the neural elements and permitting vitro-like access
for like application of pharmacological agents without the
requirement for anaesthesia.
2 | MATERIALS AND METHODS
All experiments conformed to the UK Animals (Scientific
Procedures) Act 1986 and were approved by the University of
Bristol local Ethical Review Panel. These methods are based
on those previously described for the DAPR.3,6 In the
following description an emphasis is placed on those aspects
of the technique that are different in the mouse.
2.1 | Set-up of decerebrate arterially perfused
mouse (DAPM) preparation
Male mice (CD1, 34-36 g, n= 67 (50 DAPM and 17 pithed
DAPM)) were used in these experiments (note the DAPM
could also be successfully established with adult female
mice). Mice received heparin (50 IU, ip) to prevent clot
formation twenty minutes before being anaesthetized with
isoflurane (2%) until loss of paw withdrawal reflex. After a
midline laparotomy, the stomach and intestine were vascu-
larly isolated and removed (leaving spleen, duodenum, initial
part of jejunum, and sigmoid colon). The ureters were cut
bilaterally and ligated distally to prevent bladder filling. The
thoracic cavity was opened via a midline sternotomy, causing
respiratory arrest, and gaseous anaesthesia was discontinued
(without gas exchange the deep level of anaesthesia would be
maintained). The animal was cooled by immersion into
modified Ringer's solution at 5-6°C on ice (composition
below). After craniotomy, the mouse was decerebrated, by
aspiration, at the pre-collicular level. At this point the animal
terminally exsanguinated and was formally considered dead.
The preparation was skinned then pinned to a Sylgard-
covered dissecting dish on ice. The left phrenic nerve was
identified and the lungs/diaphragm removed. An incision was
made at the cardiac apex into the left ventricular cavity for the
perfusion cannula. The right atrium and inferior vena cava
were incised to prevent venous hypertension during arterial
perfusion.
The preparation was transferred to the recording
chamber and a flushed double lumen cannula (Ø 1.2 mm,
Argyle Covidien, MA) was inserted into the ascending aorta
through the left ventricle. The end of the catheter was
passed through the aortic valve and was held in the
ascending aorta by a wedge-shaped sleeve just proximal to
the cannula tip (Figure 1A-C). The preparation was perfused
with carbogen-gassed Ringer's containing an osmotic agent,
Ficoll-70 (1.25% Sigma). The heated perfusate (31°C) was
pumped (15-20 mL/min, Watson-Marlow 505D, UK) from
a reservoir flask through bubble traps and a particle filter
(25 µm screen, Millipore). Perfusate was recycled from the
recording chamber to the reservoir. Aortic perfusion
pressure was monitored via the second lumen of the
cannula. Once perfusate flow was initiated the heart
resumed beating. Rhythmic respiratory movements of the
chest wall were seen within 5 min, indicating the return of
brainstem activity, typically as perfusion pressure reached
50-60 mmHg. However, at this perfusion pressure, coordi-
nated bladder-EUS control was often not observed and it
typically required ∼65-70 mmHg for voiding to commence,
likely reflecting the need to perfuse the distal spinal cord
adequately, as noted in the DAPR.3 This was achieved by
care with arterial haemostasis during surgical preparation. If
the initial perfusion pressure remained low then it could be
increased by addition of Angiotensin II to the perfusate,
however, overzealous use of Angiotensin II (at doses of
>100 pM) could cause deterioration of the eupnoeic
respiratory pattern, perhaps because of excessive
vasoconstriction.
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A glass suction electrode was used to record the left
phrenic nerve whose activity (PNA) was AC amplified
(5-10 k), band pass filtered (100 Hz to 3 kHz) and digitized at
10 KHz. The preparation was not paralyzed with muscle
relaxant (except where specified), in order to retain EUS
function. Therefore, the preparation displayed respiratory
movement throughout the experiments and this, alongside the
eupnoeic pattern of phrenic nerve activity, gave a continuous
index of viability.
2.2 | Lower urinary tract recordings
The pubic symphysis was cut in the midline to allow access to
the EUS.A glass suction electrode (tip diameter ∼200 µm)was
placed on the proximal sphincter slightly lateral to the midline,
directly below the bladder neck to record EUS-EMG
(Figure 1D). A reference Ag/AgCl wire electrode was fixed
close to the tip. A 27G needle was inserted into the bladder
dome and connected via saline-filled tubing to a pressure
transducer and a syringe pump (Genie, Kent Scientific,
Torrington, CT) allowing infusion of 0.9% saline. The infusion
rate was 25 μL/min (unless otherwise stated), as used in
previous mouse urodynamic studies.5 To test the experimental
utility of DAPM for the assessment of peripheral bladder
sensitization, the effect of intravesical acetic acid (0.2%) was
evaluated.
2.3 | “Pithed” DAPM
To investigate the peripheral effects of drugs by excluding
any potential effects on CNS, we established the DAPM and
then transected the cord at the medullo-spinal junction to
allow removal of the brain stem and “pithed” the spinal cord
with a blunt wire. The ablation was confirmed by a total loss
of phrenic nerve activity and of respiratory/pinch-evoked
movements. Additionally, the micturition cycle was lost and
the LUT became incontinent. Therefore, the urethra was
clamped to allow measures of filling pressure and compli-
ance. Saline was infused into the bladder to a maximum intra-
vesical pressure of 15 mmHg to avoid over-distension. For
recordings of pelvic nerve activity, the nerve was freed from
surrounding tissue proximal to the major pelvic ganglion with
fine forceps and then cut to allow access to the distal end with
a suction electrode (Figure 1E).
2.4 | Data acquisition
Perfusion pressure, phrenic nerve activity, ECG, bladder
pressure, EUS-EMG activity, and pelvic afferent neural
activity were recorded using custom built AC amplifiers and
transducers (built by Mr. Jeff Croker, University of Bristol).
Signals were digitized using a micro1401 interface
(Cambridge Electronic Design (CED), Cambridge, UK) to
a computer running Spike2 software (version 7, CED).
2.5 | Analysis
Analysis was conducted offline, using Spike2 software and
the Statistical Package for Social Sciences, version 22
(SPSS Inc., Chicago, IL). Statistical testing employed
parametric or non-parametric tests as appropriate given the
distribution of the sampled parameters as assessed by
Shapiro-Wilk normality test. All values are expressed as the
mean ± standard error or median (25-75th percentiles) and
n= number of preparations. The threshold for statistical
significance was P< 0.05.
2.6 | Drugs and solutions
The composition of Ringer's was NaCl (125 mM), NaHCO3
(24 mM), KCl (3 mM), CaCl2 (2.5 mM), MgSO4 (1.25 mM),
KH2PO4 (1.25 mM); Glucose (10 mM) pH 7.35-7.4 after
carbogenation (95% O2/5% CO2). Ficoll-70 (1.25%) was
added as an oncotic agent to the perfusate. Stock solutions of
hexamethonium (330 mM), Angiotensin II (100 nM), and
vasopressin (10 uM) were made in distilled water and kept
frozen until the time of experiment, when they were diluted in
Ringer's and perfused at the final concentration. All salts and
drugs were from Sigma.
3 | RESULTS
3.1 | Preparation viability
After the initial optimization of preparation perfusion, an
augmenting eupnoeic pattern of phrenic activity indicated
healthy brainstem function6,7 and typically lasted for periods
of 3-4 h. Respiratory movements of the thoracic cage, upper
airway muscles, and motor responses to hind limb/tail pinch
were seen throughout this phase.
3.2 | Characteristics of fluid infusion-evoked
voids
Functional neural coordination of the bladder and EUS
was clearly demonstrable in the preparation in response to
intravesical infusion of saline (25 μL/min, Figure 1F). An
initial series of experiments with direct bladder visualiza-
tion indicated that voiding was complete without any
residual urine (confirmed after each void by aspiration of
the bladder contents, n = 5). During each void, the bladder
pressure increased as the detrusor contracted and bursting
activity of the EUS was observed. The effect of this
bursting activity was visible as rhythmic contractions of
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the sphincter. Subsequently, a post-void pressure increase
was caused by isometric bladder contraction when the
EUS ceased bursting and displayed tonic activity. The
bladder pressure returned to baseline as the detrusor
relaxed after the void. The mean voided volume was
100 ± 8 μL with an inter-void interval of 240 ± 19 s
(n = 12). The full profile of voiding parameters in the
DAPM is shown in Table 1.
FIGURE 1 Continued.
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Typically, the DAPMpreparation exhibited voiding cycles
for 1-3 h (mean of 110 ± 10min (n= 12)). The end of each
experiment was signaled by the appearance of incomplete
voiding, indicated by a gradual increase in the basal bladder
pressure. This likely reflected impaired communication
between brain stem and the autonomic and motor nuclei of
the distal spinal cord, as there was still eupnoeic respiratory
activity evident on the phrenic nerve (indicating intact
brainstem communication with the cervical cord).
Most preparations showed spontaneous NVCs during the
storage phase with an average amplitude 2.6 ± 0.1 mmHg and
frequency of 1.4 ± 0.1 per minute (total 130 NVCs from
seven preparations analyzed in detail). Both the frequency
and amplitude of NVCs increased with bladder filling
(Spearman's coefficient = 0.333, P< 0.001, Figure 2A).
Rhythmic pressure waves that resulted from putative
micromotions (pMM, as previously reported8) of the bladder
wall were observed in the pithed model (Figure 2B). The
amplitude of pMM (0.69 ± 0.04 mmHg, n = 236 from 7mice)
in the pithed model was 3-4 fold smaller than amplitude of
NVC in DAPM with an intact spinal cord and brainstem
(P< 0.001). The frequency of pMM (1.7 ± 0.2 per minute
(with bladder distensions up to 15 mmHg in 7 mice)) was
similar to the frequency of NVCs in DAPM. Again, like
NVCs, the pMM showed an increasing frequency and
amplitude with bladder filling (Figures 2B-1 and 2B-2).
3.3 | Actions of vasopressin on the LUT
In the DAPR, vasopressin (200-400 pM) was used at the
beginning of the preparation, as part of tuning, to increase the
perfusion pressure and restore brainstem function.3 Accord-
ingly, vasopressin was also initially trialed for tuning the
DAPM, although it was found that higher doses of the pressor
agent (>400 pM)were required to increase perfusion pressure
above 60 mmHg. Despite achieving apparently good perfu-
sion pressure and brainstem function (eupnoeic respiratory
pattern), the DAPM commonly (>85% of the time, n= 23)
did not exhibit an appropriate micturition cycle after
application of vasopressin (2-10 nM) and even at doses in
the 200-400 pM range normal micturition appeared to be
impaired.
This observation led us to assess whether vasopressin
might be directly influencing bladder and urethral function
in mice. Therefore, the DAPM was established by tuning
with careful adjustment of flow alone to establish a
eupnoeic breathing pattern and normal voiding. Subsequent
addition of vasopressin to the perfusate (2 nM) increased
the perfusion pressure (137.1% of control, Figure 3A). It
3
FIGURE 1 Schematic of decerebrate arterially perfused mouse (DAPM) in situ preparation for bladder studies (A). The perfusion cannula is
shown with a knuckle at the tip to secure its placement in the aortic arch (B). The cannula is inserted under direct vision through the left
ventricle (C) and pushed through the aortic valve until the knuckle fits through the aortic valve tightly and the tip is visible in the proximal aorta.
(D) Lower urinary tract showing a needle inserted into the bladder dome allowing infusion of fluid and monitoring of intravesical pressure. A
suction electrode enabled simultaneous EUS-EMG activity recording. (E) Pelvic nerve of the bladder held in a suction electrode for recording of
afferent activity. (F) Consecutive micturition cycles recorded with EUS-EMG activity. Expanded time scale shown below with EUS bursting
activity during voiding. The following micturition parameters (Figure 1F) were measured (averaged over at least three voiding cycles):
• Baseline was taken as the lowest bladder pressure reached immediately following a void.
• Voiding threshold was the bladder pressure when the EUS-EMG changes its activity to bursting, indicating the initiation of voiding.
• Micturition pressure was the absolute value of the peak bladder pressure achieved during voiding (bursting phase of the EUS-EMG).
• Non-voiding contractions (NVCs) were identified as discrete increases in bladder pressure (>1 mmHg) observed during the filling phase in
voiding preparations.
• In preparations without voiding (ie, pithed DAPM) the small rhythmical pressure fluctuations with amplitude of more than 0.4 mmHg were
termed putative micromotions (pMM).
• Bladder compliance was defined as bladder capacity/(threshold—basal pressure) (μL/ΔmmHg) during filling at a rate of 25 μL/min
TABLE 1 Voiding parameters in decerebrate arterially perfused
mouse (DAPM)
Cystometrogram Mean ± SEM
Basal pressure 6.6 ± 0.4 mmHg
Threshold pressure 14.5 ± 0.9 mmHg
Micturition pressure 22.9 ± 1.5 mmHg
Infused volume 100.1 ± 7.9 μL
Inter-void interval 240.3 ± 19.0 s
Bladder compliance 14.4 ± 2.1 μL/mmHg
Non-voiding contraction frequency 1.5 ± 0.4/min
Non-voiding contraction amplitude 3.1 ± 0.5 mmHg
External Urethral Sphincter
Electromyogram
Spike frequency within burst 4.7 ± 0.3 Hz
Duration of bursting activity per void 5.2 ± 0.8 s
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also produced increases in both basal (121% of control) and
micturition (127% of control) pressure (Figure 3A-2).
Further application of 10 nM vasopressin produced an
increase in tonic EUS-EMG activity, leading to urinary
retention (Figure 3A-3).
To test for effects of vasopressin on basal pressure (with a
fill volume of 10 μL), incremental doses (0.08, 0.4, 2, and
10 nM) were added to the perfusate (at 10 min intervals).
Vasopressin increased basal bladder pressure in a dose
dependent manner (to 403 ± 46% of control with 10 nM of
vasopressin, n= 5) (Figure 3B-1). In the “pithed” DAPM
(without CNS influence) vasopressin also increased bladder
pressure (to 330 ± 34% of control, 10 nM vasopressin, n= 5)
(Figure 3B-2).
FIGURE 2 Relationship between NVCs, pMM, pelvic nerve activity and the phase of the micturition cycle. Both NVC amplitude and
frequency increased with bladder filling (A-1). The NVC amplitude and frequency showed a clear relationship to the phase of the micturition
cycle (A-2 and A-3), normalized to the largest event/interval observed in each DAPM preparation, assessed over four micturition cycles, n= 7
mice). Similar relationship was found for pMM amplitude and frequency and micturition phase (n= 7 mice, B-1, B-2, and B-3). Recording of
pelvic afferent neural activity in pithed model (C) showing relationship to bladder pressure (Cc) and to pMM (Cd). * P< 0.05, significant
difference compared to baseline with repeated measures ANOVA with Dunnett's post hoc test for multiple comparisons
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3.4 | Autonomic and sacral motor outflows are
required for active voiding and continence
Application of vecuronium (200 ng/mL), a neuromuscular
blocking drug, caused the expected decrease in EUS-EMG
activity with a loss of bursting activity during voids. This
caused incomplete voiding with a retained volume, indicating
that the actively bursting EUS in the mouse appears to be
important to facilitate urine passage through the sphincter.
Further filling caused an increase in the bladder pressure,
leading to passive leakage of fluid through the EUS, rendering
the LUT incontinent (Figure 4A; n= 3).
Systemic administration of hexamethonium (330 μM
after3), reduced arterial perfusion pressure (by 22.9 ± 2.6%,
n= 4) indicating a loss of sympathetic tone consistent with
autonomic ganglion blockade. This was not accompanied by a
change in the eupnoeic PNA indicating that brainstem
function was not compromised. The autonomic ganglion
blockade initially caused incomplete voiding, with reduced
peak voiding pressure and EUS activity and the preparation
rapidly (within 3 min) stopped voiding. With further filling
and an increase in bladder pressure then overflow urinary
retention could be observed, that is, passive leakage of urine
from the distended bladder (Figure 4B; n= 4).
3.5 | Intravesical acetic acid
After obtaining baseline recordings of five voiding cycles
acetic acid (0.2%) was infused into the bladder which
decreased the micturition interval (to 75 ± 3.8% of control)
and micturition pressure (to 75 ± 0.8% of control). The
frequency of NVCs increased (to 385 ± 4.7% of control) and
the amplitude of NVCs decreased (to 62 ± 1.3% of control).
After infusion of acetic acid, the pattern of EUS-EMG
changed to exhibit phasic activity even when the bladder was
almost empty, and the frequency of phrenic nerve activity
increased (to 132 ± 10.1% of control). (Figure 4C).
FIGURE 3 Effect of vasopressin on LUT function in the DAPM. (A) Representative recording of perfusion pressure, phrenic nerve activity,
bladder pressure, and EUS-EMG activity before and after administration of vasopressin (2 and 10 nM) showing the loss of bladder—sphincter
co-ordination manifesting as an increase in tonic activity on the EUS. (B) Direct effects of vasopressin (80 pM, 400 pM, 2 nM, and 10 nM) added
to the perfusate on perfusion and bladder pressures in pithed and DAPM model (shown graphically below). *, # P< 0.05, − P< 0.01, significant
difference compared to baseline with repeated measures ANOVA and Dunnett's test for multiple comparisons (*—DAPM and #—pithed DAPM)
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3.6 | Suitability for pelvic nerve recordings
The pelvic nerve in the mouse is small and difficult to access
so we tested the viability of recording from the nerve in the
pithed DAPM. The nerve was straightforwardly identified,
sectioned, and bipolar recordings made from the distal
cut end. This showed bladder distention-induced activity
which increased exponentially over the range of pressures
normally associated with the micturition cycle (Figure 2C).
FIGURE 4 Urinary retention caused by administration of the neuromuscular blocker, vecuronium bromide (2 μg/mL) (A) and ganglion
blocker, hexamethonium (330 μM) (B) to the perfusate. Effect of intravesical infusion of acetic acid (0.2%) on phrenic nerve activity, bladder
pressure and EUS-EMG activity (C-A; Control, C-B; After acetic acid)
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Intriguingly the pMM seen during bladder filling were
associated with increases in afferent nerve activity.
4 | DISCUSSION
We have developed and validated a novel in situ mousemodel
to investigate LUT function without the confounding effect of
anaesthesia and with some of the advantages of the
accessibility afforded by in vitro approaches. Previously,
the DAPR has proven to be useful for the study of autonomic
control and has enabled the completion of detailed LUT
investigations.3,4,6 The DAPM allows straightforward access
to the EUS and much of the LUT under direct vision. In
addition, the actions of drugs, including those that would be
toxic in in vivo, can be examined either systemically, locally,
or intravesically.
4.1 | Voiding characteristics of DAPM
The DAPM showed an intact micturition cycle of discrete,
active filling and voiding phases, with excellent reproduc-
ibility. Continuous intravesical infusion triggered the coordi-
nated active contraction of the bladder and EUS activity to
enable voiding. The EUS EMG activity showed a bursting
pattern during the void. A post-void isovolumetric pressure
increase was noted as the EUS closed (tonic EMG activity)
while the detrusor remained contracted.
The DAPM showed a similar range of cystometrogram
parameters to that observed previously in mouse studies
(reviewed in5). The micturition pressure (23 mmHg) was
within the range of previous values of in vivo ambulatory,9
urethane-anaesthetized,10 and decerebrate mice,11 although
several papers have reported higher micturition pressures
between 25 and 45 mmHg in conscious mice.5 One possible
reason for this difference may be that in the DAPM, the
bladder is not influenced by the pressure transmitted from the
abdominal wall (which has been opened) or it may relate to
the absent volitional element provided by forebrain centers. It
should be noted that the pressures generated in the DAPM
were sufficient to completely void urine from the LUT.
4.2 | Characteristics of mouse external
urethral sphincter
The entire length of the EUS can be observed clearly in the
DAPM allowing accurate placement of the electrode to
reliably obtain EMG recordings. The functional examination
of EUS is typically difficult in mouse, in part because of their
body size.12 Therefore, the co-ordinated activity of the
bladder and urethra is poorly characterized in mice, in
contrast to numerous studies in rats. The DAPM showed a
similar pattern of EUS activity to rats3,4,13 with striking
bursting activity of EUS during the void. There have been
several recent reports recording EUS-EMG in conscious,
tethered mice.11,14 These reports showed low-amplitude tonic
EUS-EMG activity between voids which increased in
amplitude during bladder contraction, falling only at the
peak of the contraction, coincident with voiding.11,14 These
studies showed no EUS bursting activity. However, bursting
activity has previously been noted in chronically implanted
mice.5 One possible reason for this difference is the challenge
of obtaining good signal to noise in tethered chronic
recordings and challenges with identifying the EUS. As
detailed, below we propose that the bursting activity is a
fundamental physiological feature of voiding in the mouse.
This may be required because of the local sphincter anatomy
and flow dynamics in the mouse (and rat) where the small
diameter and relatively long length of the ureter mean that
voiding occurs by a different mechanism than in larger
mammals.15
4.3 | Neuromuscular blockade and autonomic
ganglion blockade
Systemic administration of vecuronium and hexamethonium
both compromised voiding. Vecuronium, as expected,
decreased the electrical activity of the EUS, confirming its
mediation by striated muscle. This reduced voiding efficiency
—there were still active bladder contractions but these were
unable to completely empty the bladder contents. This
indicates that relaxation of external sphincter does not cause
passive leakage of urine in the normal range of pressures seen
in the mouse filling cycle. This also suggests that bursting
activity of EUS is required for elimination of urine in mice.
Hexamethonium also produced overflow incontinence by
disruption of parasympathetic and sympathetic activity
confirming that the voiding cycle in the DAPM requires
active contributions from the autonomic nervous system.
4.4 | Vasopressin induces urinary retention
In the DAPR, vasopressin was effective as a pressor without
any obvious influence on the micturition cycle.1,3 In the
DAPM, however, vasopressin increased bladder pressure and
impaired coordination with EUS activity, which induced
urinary retention in most cases. It appears likely that
vasopressin influences the bladder directly as we observed
the same effects of vasopressin in the “pithed” DAPM
preparation. It has been noted that vasopressin (via V1a
receptors) contracts mouse internal urethral sphincter in
vitro.16 We found higher doses of vasopressin increased
phasic EUS-EMG activity, which might also represent a
direct action of vasopressin on the sphincter. Such an action to
increase EUS sphincter tone may be responsible for the
bladder-sphincter dyssynergy.
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4.5 | Stimulation with acetic acid
Acetic acid infusion has been used as a model of peripheral
bladder sensitization17 and showed a similar profile of action
in the DAPM. Acetic acid also produced changes in
respiratory pattern indicating that the activation of bladder
afferents was signaled to a brainstem level. This indicates that
the DAPM may be useful to investigate pathophysiological
models of bladder disease including overactive bladder17 or
bladder pain syndrome.
4.6 | Subtracting central influences in the
DAPM
The “pithed” DAPM preparation proved useful to contrast
central versus peripheral mechanisms controlling the LUT, as
noted earlier for vasopressin. Additionally, in the pithed
preparation, pMM were observed whose characteristics were
similar to NVCs in the DAPM as both showed increased
amplitude and frequency with bladder filling, as previously
noted in the anaesthetized Guinea-pig.18 Recordings from the
isolated bladder of Guinea-pig suggested that spontaneous
activity originates from both the bladder mucosa and detrusor
but different pharmacological profiles,19 as yet the source of
this activity is not defined in mice. Interestingly the pMM
were sufficient to modulate pelvic afferent activity which
could be also observed in ex vivo mouse model20; perhaps
consistent with the idea that a spinal amplificationmechanism
is responsible for turning pMM into NVCs which had a larger
amplitude. The pithed DAPM reliably allowed afferent
recordings of pelvic nerve in mice whose activity increased
exponentially in the normal range of micturition pressures
(<15 mmHg), a lower range than that previously seen with in
vitro recordings of mouse pelvic activity.21
5 | SUMMARY
We report a novel in situ preparation, the DAPM, and
demonstrate its utility for studies of the LUT, but we note that
it is likely to be useful for studies of other viscera/locomotion
and their nervous control. Particular advantages are the speed
and ease of set up, lack of need for anaesthesia, and the
straightforward access the urogenital organs including the
bladder and urethra in the adult mouse. The preparations
showed good experimental reproducibility increasing power
to identify differences which meant that relatively low
numbers of animals were required in each protocol. Potential
drawbacks of the preparation include the duration of viability
(up to 3 h). Preparation viability showed a strong temperature
dependence (as we have previously noted for in situ
preparations) and 31°C appeared an optimal compromise.
Additionally, the loss of forebrain control centers that are
known to regulate the volitional and behavioral control of
voiding precludes analysis of their contribution.22 By way of
compensation, the DAPM offers the potential to visualize
bladder and urethra movements, which can be video captured
allowing relation of electrophysiology to the bladder
movement.23 The potential to combine with bladder sheet
and Ca2+ imaging experiments24 or optogenetic approaches25
might bring new insights to the relationship of urothelial
transmitters and central nervous system activity.
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